TD Cowen Keeps Their Buy Rating on Nautilus Biotechnolgy (NAUT)
Goldman Sachs Reaffirms Their Hold Rating on Nautilus Biotechnolgy (NAUT)
Morgan Stanley Reiterates Equal-Weight on Nautilus Biotechnology, Maintains $6 Price Target
Nautilus Biotechnology Analyst Ratings
Nautilus Group (NLS) Initiated With a Hold at Craig-Hallum
Craig-Hallum Keeps Their Buy Rating on Nautilus Group (NLS)
Nautilus Analyst Ratings
No Data